Vaccine trials open officially
Thursday 1 April 2004
Home About PlusNews Country Profiles News Briefs Special Reports Subscribe Archive IRINnews


East Africa
Great Lakes
Horn of Africa
Southern Africa
·South Africa
West Africa


Country Profiles
Conferences / Research
Job opportunities

News Briefs

AFRICA: Fear of new AIDS-like virus through bushmeat
AFRICA: Crisis-level HIV/AIDS response urged
SOUTH AFRICA: MRC announces traditional anti-AIDS medicine trials
PlusNews E-mail Subscription

BOTSWANA: Vaccine trials open officially


Botswana has the highest HIV prevalence

GABORONE, 8 July (PLUSNEWS) - The first trial of an experimental AIDS vaccine in Southern Africa began this week in Botswana with the enrollment and injection of the first two volunteers at the Princess Marina hospital in the capital, Gaborone.

"This study is a significant and hopeful step in Botswana's battle against the scourge of AIDS," said Joy Phumaphi, Botswana's Health Minister. "The volunteers of this trial exemplify the best of the traditional Botswana values of altruism and selflessness. They are true heroes in this fight for our country's future."

The research is a joint initiative by the Ministry of Health and the Botswana-Harvard AIDS Institute Partnership (BHP), established in 1996 by the Botswana Government and the Harvard AIDS Institute. Phase 1 of the trials, currently being conducted, is open to individuals between the ages of 21 and 40, who are in general good health, HIV negative, available for 18 months, not pregnant and intending to remain so during the course of testing.

BHP hope approximately 14 HIV-negative volunteers, from an initial group of 30 Batswana participating so far, will be enrolled. Potential volunteers continue to be screened.

The experimental vaccine is composed of a non-infectious component of HIV's genetic material. "These components do not cause infection, so there is no chance that trial volunteers could get HIV infection from receiving the experimental vaccine," said Joseph Makhema, BHP Co-Director and Senior Clinical Research Manager.

During the study, side effects will be examined to determine the vaccine's safety at three different dosages, and the body's immune response.

The vaccine was developed by Epimmune, a company based in San Diego, California. The BHP HIV Reference Laboratory is an ultramodern research facility that is also helping to build Botswana’s professional capacity by training the nation's future researchers and technicians.

BHP is designed to identify opportunities for collaborative research, as well as pursue education activities in the fight against HIV/AIDS.

"The government of Botswana deserves recognition for the creation of the BHP laboratory and the capacity it has built with trained staff, state-of-the-art equipment and Botswana-specific research," noted Dr Max Essex, BHP Chairman. "Botswana stands ready to conduct not only this study, but other important HIV research. It is important to stress that the road to a successful vaccine is long, and that this phase 1 trial is a first step for Botswana on that road."



Recent BOTSWANA Reports

Few women accessing PMTCT services,  23/Mar/04
Interview with Dr Ndwapi Ndwapi, director of Princess Marina Hospital's ARV programme ,  11/Mar/04
Gaps remain in AIDS knowledge,  11/Mar/04
All public health facilities to offer HIV testing,  20/Oct/03
Women living with HIV caring for each other,  23/Sep/03


The Global Fund to fight AIDS, Tuberculosis & Malaria
International Community of Women Living with HIV/AIDS
The Global Fund to fight AIDS, Tuberculosis & Malaria
International HIV/AIDS Alliance

PlusNews does not take responsibility for info in links supplied.


PlusNews is produced under the banner of RHAIN, the Southern African Regional HIV/AIDS Information Network. RHAIN's members currently include:


  • IRIN

  • Inter Press Service (IPS)



  • Health Systems Trust

  • Health & Development

  • GTZ/Afronets

[Back] [Home Page]

Click to send any feedback, comments or questions you have about IRIN's Website or if you prefer you can send an Email to

The material contained on this Web site comes to you via IRIN, a UN humanitarian information unit, but may not necessarily reflect the views of the United Nations or its agencies. If you re-print, copy, archive or re-post any item on this site, please retain this credit and disclaimer. Quotations or extracts should include attribution to the original sources. All graphics and Images on this site may not be re-produced without the express permission of the original owner. All materials copyright © UN Office for the Coordination of Humanitarian Affairs 2004